Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...

Thus, candidates should be tested against a panel of receptors at the time of antibody engineering. ACROBiosystems provides an extensive collection of recombinant Fc receptor proteins, which ...

Previous studies established defective Fc receptor mediated clearance in patients with systemic lupus erythematosis (SLE), a disorder associated with circulating immune complexes (CIC).

The binding between a biosimilar and its target antigen (and Fc receptors) is regarded as a key indicator of its efficacy. ACROBiosystems has designed high-quality target antigen proteins and Fc ...

HOUSE, Pa. - Johnson & Johnson (NYSE: NYSE:JNJ) has released new data on nipocalimab, an investigational drug with potential to treat diseases driven by immunoglobulin G (IgG) antibodies. Published in ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with ...

Here we describe a mouse Fc receptor, designated Fcα/μR, and its human homolog, that bind both IgM and IgA with intermediate or high affinity. Fcα/μR is constitutively expressed on the ...

Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Immunovant is a clinical-stage biopharmaceutical company focused on the development of treatments for autoimmune diseases through monoclonal antibodies targeting the neonatal Fc receptor FcRn.